Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Briefs: CMS Add-On Payment Deadline; Advanced Imaging Accreditor; Ventilator Payments

This article was originally published in The Gray Sheet

Executive Summary

Applications are due Nov. 25 for companies seeking new-technology add-on payments, CMS announces. Agency names RadSite as a national accreditor for suppliers of advanced imaging equipment. More reimbursement news.

You may also be interested in...



People Briefs: Cook Medical Names President; Smith & Nephew Gains Chairman-Elect

Cook Medical appoints a new president. Smith & Nephew names Roberto Quarta chairman-elect. Mela Sciences appoints Rose Crane president and CEO.

Medicare Bonus Payments Awarded To Cook’s Stent, Second Sight’s Eye Implant

Cook Medical’s Zilver PTX stent and Second Sight Medical Products’ Argus II retinal prosthesis system will enjoy new-technology add-on payments in 2014 under CMS’ hospital inpatient prospective payment system final rule.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel